D.A. Davidson & CO. Sells 8,638 Shares of Gilead Sciences, Inc. $GILD

D.A. Davidson & CO. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 62,427 shares of the biopharmaceutical company’s stock after selling 8,638 shares during the period. D.A. Davidson & CO.’s holdings in Gilead Sciences were worth $6,921,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in GILD. Price T Rowe Associates Inc. MD boosted its stake in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. Nuveen LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at about $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $238,083,000. Los Angeles Capital Management LLC boosted its stake in shares of Gilead Sciences by 422.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Gilead Sciences by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.6%

Shares of NASDAQ GILD opened at $120.74 on Friday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The stock has a market cap of $149.82 billion, a P/E ratio of 24.05, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. The firm has a 50-day moving average of $115.41 and a 200 day moving average of $110.89. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period last year, the company posted $2.01 EPS. Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s payout ratio is 62.95%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GILD. BMO Capital Markets lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research note on Monday. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price on the stock in a research note on Tuesday, August 19th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Finally, Wolfe Research lifted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $122.61.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer directly owned 595,725 shares of the company’s stock, valued at $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,500 shares of company stock valued at $8,281,540. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.